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A systematic review of intervention studies examining nutritional and herbal
therapies for mild cognitive impairment and dementia using neuroimaging
methods: study characteristics and intervention efficacy
Abstract
Neuroimaging facilitates the assessment of complementary medicines (CMs) by providing a noninvasive
insight into their mechanisms of action in the human brain. This is important for identifying the potential
treatment options for target disease cohorts with complex pathophysiologies. The aim of this systematic
review was to evaluate study characteristics, intervention efficacy, and the structural and functional
neuroimaging methods used in research assessing nutritional and herbal medicines for mild cognitive
impairment (MCI) and dementia. Six databases were searched for articles reporting on CMs, dementia,
and neuroimaging methods. Data were extracted from 21/2,742 eligible full text articles and risk of bias
was assessed. Nine studies examined people with Alzheimer's disease, 7 MCI, 4 vascular dementia, and 1
all-cause dementia. Ten studies tested herbal medicines, 8 vitamins and supplements, and 3 nootropics.
Ten studies used electroencephalography (EEG), 5 structural magnetic resonance imaging (MRI), 2
functional MRI (fMRI), 3 cerebral blood flow (CBF), 1 single photon emission tomography (SPECT), and 1
positron emission tomography (PET). Four studies had a low risk of bias, with the majority consistently
demonstrating inadequate reporting on randomisation, allocation concealment, blinding, and power
calculations. A narrative synthesis approach was assumed due to heterogeneity in study methods,
interventions, target cohorts, and quality. Eleven key recommendations are suggested to advance future
work in this area.
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Neuroimaging facilitates the assessment of complementary medicines (CMs) by providing a noninvasive insight into their
mechanisms of action in the human brain. This is important for identifying the potential treatment options for target disease cohorts
with complex pathophysiologies. The aim of this systematic review was to evaluate study characteristics, intervention efficacy,
and the structural and functional neuroimaging methods used in research assessing nutritional and herbal medicines for mild
cognitive impairment (MCI) and dementia. Six databases were searched for articles reporting on CMs, dementia, and neuroimaging
methods. Data were extracted from 21/2,742 eligible full text articles and risk of bias was assessed. Nine studies examined people
with Alzheimer’s disease, 7 MCI, 4 vascular dementia, and 1 all-cause dementia. Ten studies tested herbal medicines, 8 vitamins and
supplements, and 3 nootropics. Ten studies used electroencephalography (EEG), 5 structural magnetic resonance imaging (MRI),
2 functional MRI (fMRI), 3 cerebral blood flow (CBF), 1 single photon emission tomography (SPECT), and 1 positron emission
tomography (PET). Four studies had a low risk of bias, with the majority consistently demonstrating inadequate reporting on
randomisation, allocation concealment, blinding, and power calculations. A narrative synthesis approach was assumed due to
heterogeneity in study methods, interventions, target cohorts, and quality. Eleven key recommendations are suggested to advance
future work in this area.

1. Introduction
Dementia is a syndrome comprising over 100 diseases and is
characterised by a decline in cognition that interferes with

function and independence [1]. Over 46.8 million people
worldwide have a diagnosis of dementia [2], and currently
there is no cure. Dementia has a heterogeneous pathophysiology, with multiple mechanisms thought to play a role in
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the various types. For example, there are several hypotheses
on the pathogenesis of Alzheimer’s disease (AD) alone (the
most common type of dementia, making up approximately
60–80% of all cases [3]) including the amyloid-beta peptide
hypothesis, the inflammation hypothesis, the tau hypothesis,
and the cholinergic hypothesis [4]. Oxidative stress, hypoxia,
calcium imbalance, abnormal metal accumulation, amyloidbeta peptide accumulation within mitochondria, and brainspecific insulin signalling deficiencies are all thought to play a
role in the complex pathophysiology of AD [5, 6]. Because of
this, first-line single target pharmacological therapies for AD,
acetylcholinesterase (AChE) inhibitors (e.g., donepezil) and
N-methyl-D-aspartate (NMDA) receptor antagonists (e.g.,
memantine), are not particularly effective, boosting cognitive
function in the early disease stages only, and are unable to
slow or stop the disease progression [7, 8].
In the absence of effective pharmaceutical options for
dementia, complementary medicines (CMs) have been thoroughly explored. Randomised-controlled trials (RCTs) have
been conducted on a range of CMs for dementia, cognitive decline, and mild cognitive impairment (MCI), with
many studies currently ongoing. This research has largely
focused on nutritional and herbal medicine interventions
(e.g., resveratrol, anthocyanins, fish oil, vitamins B and E,
Ginkgo biloba, Curcuma longa, Bacopa monnieri, and multiherb formulas such as Sailuotong [SLT]), dietary interventions (e.g., ketogenic and Mediterranean diets), mind-body
interventions (e.g., mindfulness, yoga, tai chi, and other types
of physical activity), and manual therapies (e.g., acupuncture), and has yielded mixed results due to a range of methodological inconsistencies. Therapies that show potential as
adjunct treatments for dementia, or prevention methods,
should be thoroughly investigated with the most rigorous and
objective measures to reduce sources of bias.
Neuroimaging techniques can provide an objective, precise, and noninvasive measure of neuronal function and are
particularly useful in the assessment of complementary therapies for dementia. Popular functional techniques applied in
CM research include electroencephalography (EEG), functional magnetic resonance imaging (fMRI), positron emission tomography (PET), magnetoencephalography (MEG),
single photon emission computed tomography (SPECT), and
functional near-infrared spectroscopy (f NIRS). Structural
magnetic resonance imaging (MRI) and diffusion tensor
imaging (DTI) can also be used to assess changes in
morphology following longer interventions. As detailed in
Table 1, depending on study characteristics such as the sample’s degree of cognitive impairment, intervention type and
duration, neurocognitive function of interest, and reasons
for using neuroimaging, these methodologies have a range
of advantages and limitations that should be considered
carefully before a specific technique is applied in a CM dementia research study.
Neuroimaging, in particular functional neuroimaging,
can be utilised in dementia CM research as a sensitive measure of neurocognition, with the capacity to record changes
that cannot otherwise be detected by standard pen-andpaper neuropsychological tests. This is useful given the small
effect sizes often reported in CM research, particularly acute
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studies, and that any proposed intervention for cognitive
decline is effectively fighting an uphill battle against neurodegenerative pathophysiology. Furthermore, some techniques
can be used to explore the mechanisms of action of a therapy,
which is particularly useful in psychopharmacological studies
(e.g., nutritional and herbal medicines).
The aim of this systematic review was three-fold: (1) provide a comparison and critical evaluation of the characteristics of studies assessing nutritional and herbal medicines for
MCI and dementia; (2) evaluate their use of structural and
functional neuroimaging methods; (3) summarise intervention efficacy. The Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [9] was
followed during the planning, conduct, and writing of this
review.

2. Methods
2.1. Eligibility Criteria. Several initial scoping reviews were
conducted to determine the eligibility criteria and review
scope. Eligibility criteria were determined in line with the
PICO principles for systematic reviews [10]:
(i) Population. People with cognitive decline, MCI, or
dementia
(ii) Intervention. Chronic CM treatment
(iii) Comparisons. Placebo or control group
(iv) Outcome. Structural or functional neuroimaging
method
Peer-reviewed studies were included if they reported a
herbal or nutritional intervention for MCI or dementia and
either structural or functional neuroimaging as an outcome
measure. It should be noted that the search strategy was intentionally kept broad and also included both mind-body (e.g.,
yoga) and manual treatments (e.g., acupuncture); due to the
large volume of results, only studies assessing nutritional and
herbal interventions were included. Reviews, commentaries,
conference proceedings, editorials, preclinical (in vitro and in
vivo), and acute clinical studies were excluded, as were studies
that were not published in English, or when the full text could
not be retrieved.
2.2. Search Strategy. The research team and an experienced
librarian reviewed the search strategy before systematic
searching commenced. Six databases were searched for
studies published in peer-reviewed journals. Abstracts were
retrieved from PubMed, ScienceDirect, Web of Science,
ProQuest, Scopus, and PsycINFO ranging from databases’
dates of inception to August 28, 2016. A full list of keywords
and an example of the search strategy for the Scopus database
are detailed in Supplementary Material available online
at https://doi.org/10.1155/2017/6083629 (Table S1). Similar
searches were carried out in the other five databases, with only
minor modifications to permit changes in the use of searching
symbols. Reference lists of key articles were also searched for
other eligible studies.

Quantifies changes in brain
blood flow and metabolism.
Nuclear gamma camera captures
Regional CBF.
a gamma-emitting tracer being
absorbed by brain tissue at the
same rate as blood flow.

Typically assesses regional brain
glucose metabolism by detecting
Regional CBF.
gamma rays emitted by a
positron-emitting tracer.

fMRI

SPECT

PET

MEG

Resting state: Region of interest
Measures changes in brain blood functional connectivity
flow caused by neuronal activity. approach.
Event-related: BOLD response.

EEG

Similar to EEG, resting state
measures (delta, theta, alpha,
beta, gamma band power) and
event-related measures are
available.

Quantifies the electrical activity
of the brain generated by
electrical field potentials from
excitatory and inhibitory
neuronal activity.

Measures magnetic fields
generated by the electrical
activity of the brain.

Very high temporal resolution,
relatively inexpensive,
noninvasive, portable options
available.

Resting state EEG spectral
activity (delta, theta, alpha, beta,
gamma): power analyses and
scalp-based functional
connectivity measures
(coherence, phase-lag).
Event-related measures: ERPs,
EPs, SST, and ERSP including
ERS and ERD.
Poor spatial resolution due to
volume conduction.∗
Not as well-suited to
investigations of subcortical
dementia.

Limitations

Captures changes in
cognitive and/or sensory
function that can have their
source localised in the brain.

Relevance in CM dementia
research
Captures subtle changes in
cognitive and/or sensory
function.
Allows for the mechanisms
of action of CM therapies to
be explored.
Noninvasive and portable
options increase its usability
in groups with more
significant impairments.
Suitable for acute and
chronic studies.

Useful in assessing
interventions for dementia
as SPECT can differentiate
Administration of radioactive
Relatively cheap compared to
dementia pathologies (e.g.,
isotope (usually injection) and
other functional imaging
vascular dementia versus
exposure to gamma radiation.
methods (e.g., PET, fMRI).
Alzheimer’s disease).
Low spatial resolution (1 cm).
Allows for the mechanisms
of action of CM therapies to
be explored.
Different isotopes allow for
tagging of different
biochemical processes (e.g.,
Different novel isotopes allow
FDG-PET for glucose
distinction between Alzheimer’s Administration of radioactive
uptake, or PiB-PET for
pathology and other dementias isotope.
amyloid imaging).
(PiB-PET).
Allows for the mechanisms
of action of CM therapies to
be explored.
Captures subtle changes in
cognitive and/or sensory
Very high temporal resolution,
Detects only tangential
function.
and better spatial resolution (i.e., components of current source, so Allows for the mechanisms
more accurate) compared to
primarily sensitive to activity
of action of CM therapies to
EEG.
within sulci.
be explored.
Suitable for acute and
chronic studies.

Poor temporal resolution: the
BOLD response lags by 1-2 s
Good spatial resolution,
behind the actual neuronal
particularly with high resolution activity. Claustrophobia and
scanners (e.g., 7 T).
high-pitched noises can make
scanning uncomfortable for
participants.

Advantages

Quantification

Description

Neuroimaging
technique

Table 1: Neuroimaging technique, description, example quantification methods (by no means exhaustive), advantages, limitations, and relevance in CM studies on people with dementia.
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Good spatial resolution,
No functional information
particularly with high resolution
available.
scanners (e.g., 7 T).
Exploration of brain networks is
becoming increasingly popular
No functional information
within the field.
available.
Better resolution with more
angles (e.g., 61 direction scan).

Structural MRI images the
Most frequently used measures
anatomy of the brain using
are voxel-based morphometry
magnetic fields, radio waves, and
and ROI analyses.
field gradients.

Measures diffusion of water in
order to provide information on
tissue microstructures so that
Tractography and tensor
white matter pathways within
estimation.
and between brain regions can be
explored.

MRI

DTI

Relevance in CM dementia
research
CM intervention-associated
changes in CBF can be
ascertained.
Mechanism of action can be
explored due to the
modulation of haemoglobin.
Volumetric changes in brain
regions (or whole brain) can
be investigated.
Any changes are best
explored in chronic studies.
White matter integrity and
structural network
connectivity can be
explored.
Any changes are best
explored in chronic studies.

Note. BOLD = blood oxygenation level dependent; CBF = cerebral blood flow; CM = complementary therapies; DOT = diffuse optical tomography; DTI = diffusion tensor imaging; EEG = electroencephalograph;
EPs = evoked potentials; ERD = event-related de-synchronisation; ERPs = event-related potentials; ERSP = event-related spectral perturbation; ERS = event-related synchronisation; FDG-PET = fluorodeoxyglucosepositron emission tomography; MRI = magnetic resonance imaging; MEG = magnetoencephalograph; NIRI = near-infrared imaging; NIRS = near-infrared spectroscopy; PET = positron emission tomography;
PiB-PET = Pittsburgh compound B-positron emission tomography; ROI = region of interest; SPECT = single photon emission computed tomography; SST = steady-state topography.
∗
Can be addressed to a certain extent in connectivity analyses which partial out instantaneous zero-phase contributions.

Limitations when trying to
measure activity in subcortical
tissue.

Noninvasive and portable.

Limitations

f NIRS

Advantages

f NIRS captures changes in blood
flow by detecting haemoglobin A range of measures are used,
concentrations through the
DOT or NIRI being popular
transmission and absorption of forms of f NIR.
NIR light.

Quantification

Description

Neuroimaging
technique

Table 1: Continued.
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Table 2: Risk of bias scale item descriptions.
Risk of
bias item

Label

Description

1
2

Random sequence generation
Allocation concealment

3

Participant characteristics

4

Blinding of participants, personnel, and
outcome assessors

5

Intervention description

6

Neuroimaging methodology

7

Outcome measurement validity and
reliability

8

Selective reporting

9

Adverse events

10

Reporting of power calculation and attrition
rate effect on power

Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Are the characteristics of the participants included in the study clearly
described (inclusion/exclusion criteria)?
Was knowledge of the allocated intervention adequately prevented
during the study?
Is the intervention of interest sufficiently described to allow
replication?
Are the neuroimaging methods clearly described? Description should
include data-acquisition parameters and pre- and postprocessing
pipelines.
Were the outcome measures used accurate and appropriate (valid and
reliable)?
Were all outcome measures detailed in the methods reported in the
results?
Have all important adverse events that may be a consequence of the
intervention been reported?
Was a power calculation reported and was the study adequately
powered to detect hypothesised relationships?

Note. Items rated as “yes” were scored as 1. Items rated as “no” or “unable to determine” were both scored as 0. Higher scores indicate a lower risk of bias.

2.3. Data Extraction and Appraisal. One reviewer examined
the titles and abstracts of each article. If there was any
doubt regarding the eligibility of an article, the full-text was
retrieved for clarification. Articles deemed eligible by one
reviewer were further assessed by two other independent
reviewers to ensure inclusion criteria were met. Any disagreements were resolved by reviewing the full papers and a
subsequent discussion.
Study characteristics were extracted from each full-text
article. Data extracted included title, authors, publication
date, aim, study type, disease focus, study population characteristics, number of participants (target cohort and controls), age (mean/median and SD), gender ratio, participant
recruitment, diagnostic criteria, neuroimaging technique and
analysis method, neuropsychological test battery, definition
and dosage of CM, length of intervention, follow-up, and
findings.
An assessment of methodological risk of bias in individual studies was conducted. A 10-item scale was constructed
to suit the relevancy of studies in this review. The scale was
informed by the Cochrane Handbook [11] and the Quality
Checklist for Healthcare Intervention Studies [12] (detailed in
Table 2) to capture major sources of bias including selection
bias, internal and external validity bias, reporting bias, and
statistical bias. For each study, the following elements were
assessed: random sequence generation, allocation concealment, sampling, blinding, intervention description, neuroimaging methodology, validity and reliability of outcome
measures, selective reporting, adverse events, and statistical
power. Each of the 10 items on the scale were rated as yes
(scored as 1), no, or unable to determine (both scored as 0),
allowing higher scores to indicate a lower risk of bias. Studies
with total scores ≥ 9 were considered to have a low risk of bias.

As there was substantial heterogeneity across included
studies (in neuroimaging methods, intervention types, and
study quality), quantitative analyses (i.e., meta-analysis) were
not appropriate. Consequently, this review assumed a qualitative approach with a narrative analysis. The characteristics
of each study were extracted, and data were described using
a narrative synthesis approach.

3. Results
3.1. Study Selection. Figure 1 illustrates the study selection
process. Twenty-one studies [13–33] met the inclusion criteria
for review. Three studies [16–18] reported results from the
same RCT; the other 18 papers contained unique studies.
Ten studies assessed herbal medicines [13, 19, 21, 23, 26, 29–
33], 8 focused on vitamins and supplements [15–18, 22, 25,
27, 28], and 3 were on nootropics [14, 20, 23] (i.e., cognitive
enhancers).
3.2. Study Characteristics. Table 3 details a summary of
the characteristics of the 21 studies including aims, setting,
population, intervention type and duration, neuroimaging
methods and measures, efficacy of intervention, adverse
events, adherence, and retention. Most (𝑛 = 15) studies
included 1 intervention and 1 control group [13–20, 22, 24, 29–
33], 1 study had 3 parallel arms [28], and five studies had no
control group [21, 23, 25, 26, 34]. Four studies were carried
out in China [13, 31–33], 3 each in Japan [23, 26, 30] and
the United Kingdom [16–18], 2 each in Italy [27, 28] and
Germany [19, 22], and 1 each in the United States [14], Austria
[20], Sweden [25], Greece [29], Romania [24], and Korea
[21]. One study was a multisite RCT carried out in Belgium,
France, Germany, Italy, the Netherlands, and Spain [15]. Three
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Initial database search:
PubMed N = 668
ScienceDirect N = 484
Web of Science N = 676
ProQuest N = 539
Scopus N = 290
PsycINFO N = 85
Total N = 2,742
Did not meet inclusion criteria
(cohort, intervention, and neuroimaging):
N = 2,575
Records after initial abstract
screening:
N = 167
Duplicates:
N = 49
Records after duplicate removal:
N = 118
Not accessible:
N=7
Did not meet inclusion criteria
(non-English, protocols, abstracts):
N = 29
Full text assessed for eligibility:
N = 82

Studies included in qualitative synthesis:
N = 21

Full text excluded for not meeting specific
criteria:
Case studies N = 6
In vitro/in vivo studies N = 18
Reviews N = 25
Cross-sectional studies N = 12
Total N = 61

Figure 1: Flow diagram illustrating the study selection process.

studies were published in the 1990s [19, 20, 26], 5 studies were
published between 2000 and 2004 [14, 25, 27, 28, 30], and the
other 13 were published after 2010 [13, 15–18, 21–24, 29, 31–33].

studies [13–16, 18–33] measured global cognition at baseline
with the mini mental state examination (MMSE: mean score
= 22.0, SD = 2.5).

3.2.1. Participants. Across all the included studies (taking
into account the 3 studies on the same RCT [16–18]), the total
sample size was 𝑁 = 1,055 (476 males, 569 females, 1 study
with 10 participants did not specify sex [26]; mean age = 70.9,
SD = 6.8 years), with individual studies ranging from 8 to
179 participants, and 3 studies with less than 20 participants
[21, 23, 26]. Sample size was determined with a priori power
calculation in 3 studies [15, 18, 20], all of which achieved target
sample size.
Nine studies tested 399 participants with AD [13, 15,
19, 21, 23, 25–28], 7 studies examined 319 participants with
MCI [16, 17, 22, 23, 29, 31, 32], 4 studies analysed 156
participants with vascular dementia (VaD) [14, 24, 25, 33],
1 study explored 112 participants with unspecified dementia
(all cause) [20], 1 study examined 9 participants with mixedtype dementia (combined AD and vascular pathologies) [25],
and 1 study included 60 age-matched controls [28]. Twenty

3.2.2. Recruitment. Four studies recruited from memory
clinics [14, 15, 22, 29], 3 from the community [16–18], 2 from
both hospitals and the community [31, 32], 2 from hospital
outpatients [25, 30], 2 from hospital inpatients [13, 33], 1 from
a medical centre [21], 1 from a nursing home [20], 1 from
both outpatient clinics and the community [34], and 1 from
a university clinic [23], and 5 did not specify a recruitment
location [19, 24, 26–28].
3.2.3. Intervention Design. All studies examined chronic
administration with treatment duration ranging from 4
weeks [24, 25] to 2 years [16–18], with most chronic studies
(𝑛 = 8) assessing the effects of a 12-week intervention [13, 19,
21, 26, 30–33]. Ten studies tested herbal interventions [13, 19,
21, 23, 26, 29–33], 8 assessed vitamins (B or E) [16–18, 25, 27,
28] or supplements [15, 22], and 3 tested nootropics [14, 20,
24]. Across all studies, 18 administered an oral intervention,

Aim: to investigate the
effect of Souvenaid on
brain-activity based
networks in people with
AD.
Recruitment location:
AD medical centres.

Cohen et al.
(2003) [14],
USA

de Waal et al.
(2014) [15],
Belgium,
France,
Germany,
Italy, The
Netherlands,
Spain
Mild AD (𝑁 = 179;
drug-naı̈ve): randomised
to Souvenaid (45M : 41F,
74.1 ± 6.8 yrs, MMSE 25.1
± 2.9) or placebo
(47M : 46F, 72.5 ± 8.0 yrs,
MMSE 25.4 ± 2.7).

Aim: to investigate
whether citicoline
improves
neurocognition &
neuroimaging in people
with VaD.
Recruitment location:
specialty care centre
(memory & cognitive
disorders clinic).

Intervention: 1 × 125 mL
drink (active Souvenaid or
isocaloric control) per day.
Duration: 24 weeks.
Follow-up: 12 & 24 weeks.

Intervention: 2 × 500 mg
citicoline (or placebo) per
day, orally.
Duration: 12 months.
Follow-up: 6 & 12 months.

VaD (𝑁 = 30):
randomised to citicoline
(7M : 8F, 78.1 ± 5.8 yrs,
MMSE 19.0 ± 4.7) or
placebo (5M : 10F, 78.0 ±
5.1 yrs, MMSE 21.3 ± 2.9).

Aim: to test the efficacy
Bi et al. (2011) of fuzhisan (FZS) in
[13],
people with AD.
China
Recruitment location:
hospital patients.

EEG functional
connectivity networks
NTB: MMSE, COWAT,
RAVLT, TMT, WMS-R
[digit span, verbal paired
associates].

MRI total brain volume
MRI SH volume
NTB: BNT, COWAT,
CVLT, DRS, Grooved
Pegboard Test, MMSE,
RCFT, TMT, WAIS-R
[block design, digit span
& symbol, similarities,
vocabulary], WMS-R
[logical memory, visual
reproduction].

Intervention: 1 × 10 g FZS
(or placebo) per day, orally.
Duration: 12 weeks.
Free from over-the-counter PET (30 min)
medications for at least 2
NTB: MMSE, ADAS-cog,
weeks prior to study entry; NPI.
free from psychotropic
drugs for at least 4 weeks
prior.

Mild to moderate AD
(𝑁 = 25): randomised to
FZS (7M : 5F,
72.50 ± 6.90 yrs, MMSE
19.58 ± 3.23, ADAS-Cog
33.58 ± 6.24, NPI 19.50 ±
6.24) or placebo (6M : 4F,
68.60 ± 6.35 yrs, MMSE
19.70 ± 3.30, ADAS-Cog
34.50 ± 5.80, NPI 19.80 ±
6.11).

Neuroimaging and
neuropsychological
measures

Intervention and duration

Aim, recruitment

Study population

Author
(reference)

Efficacy on cognition, neuroimaging
measures, any associations, adherence,
retention, and adverse events
Cognition: significant but small
improvements in ADAS-Cog and NPI
scores (versus no change in placebo).
Neuroimaging: increased or stabilised
rCMRglc across frontal, parietal, and
temporal cortices, posterior cingulate
gyrus, hippocampus, thalamus, cerebellum
(versus decreased rCMRglc in placebo).
Retention: total 3 withdrew: 1x FZS, 2x
placebo (i.e., 88% completion rate).
Adverse effects: 2x mild, transient
side-effects (1x nausea, 1x constipation).
Cognition: no difference between citicoline
and placebo in neuropsychological
performance (i.e., both groups significantly
declined from baseline to both 6- and
12-month follow-up).
Neuroimaging: no difference between
citicoline and placebo in structural brain
measures (i.e., both groups had
significantly decreased total brain volume
& increased SH from baseline to 12-month
follow-up).
Retention: total 9 withdrew prior to
follow-up: 4x citicoline, 5x placebo.
Cognition: no relationship between EEG
network and NTB memory performance.
Association between beta activity and
memory performance at midpoint in the
treatment group only.
Neuroimaging: decreased beta network
EEG in the placebo but not Souvenaid
group.
Suggests improved synaptic integrity and
function and counteraction of network
decline.
Retention: total 12 withdrew prior to
follow-up; 14 excluded due to protocol
deviations &/or <80% compliance: 4x
Souvenaid, 10x placebo.

Table 3: Summary of study characteristics, intervention, neuroimaging, and neuropsychological methodologies, efficacy, and study design.

Randomised,
doubleblind,
placebocontrolled,
multisite
trial.

Randomised,
doubleblind,
placebocontrolled
trial.

Randomised,
doubleblind,
placebocontrolled
pilot study.

Study design
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Aim, recruitment

Intervention: 80 mg/d GBE
AD (𝑁 = 42): randomised
(or placebo), orally.
to GBE (14M : 7F, 63.6 yrs)
Duration: 3 months.
or placebo (14M : 7F,
Follow-up: 1, 2, and 3
63.6 yrs).
months.

Aim: to investigate the
effect of Ginkgo biloba
special extract (GBE;
EGb 761) treatment on
brain activity in people
with AD.

Heo et al.
(2016) [21],
Korea

Hofferberth
(1994) [19],
Germany

Intervention: high dose
B-vitamin treatment (folic
acid 0.8 mg/d, vit. B6
(pyridoxine HCl) 20 mg/d,
vit. B12 (cyanocobalamin)
0.5 mg/d).
1x active or placebo tablet
per day.
Duration: 24 months.

Intervention and duration

Intervention: 4.5 g/d KRG,
orally (total powder
AD (𝑁 = 14; 3M : 11F,
capsule, 6-yr-old root;
74.93 ± 7.63 yrs, K-MMSE KT&G Corporation,
19.93 ± 4.80).
Daedeok District, Korea;
8.54% Ginsenosides).
Duration: 12 weeks.

MCI (𝑁 = 156) [15]:
randomised to B-vitamin
(33M : 47F, 77 ± 5 yrs,
MMSE 28.5 ± 1.5) or
placebo (27M : 49F, 76 ±
4 yrs, MMSE 28.5 ± 1.5).
MCI (𝑁 = 168) [19, 20]:
randomised to B-vitamin
(35M : 50F, 77.0 ± 5.2 yrs,
MMSE 28.3 ± 1.8) or
placebo (31M : 52F, 76.2 ±
4.5 yrs, MMSE 28.3 ± 1.5).

Study population

Aim: To investigate the
effect of Korean red
ginseng (KRG) on brain
activity in people with
AD.
Recruitment location:
medical centre.

Aim: (1) to investigate
the effect of B-vitamin
treatment on brain
atrophy in people with
Douaud et al. MCI. (2) To investigate
(2013) [16],
the effect of (a) plasma
Jernerén et al. 𝜔-3 fatty acid
(2015) [17] and concentrations, (b)
Smith et al.
plasma tHCy
(2010) [18],
concentrations, on
UK
B-vitamin treatment of
brain atrophy in people
with MCI.
Recruitment location:
community.

Author
(reference)

EEG (theta/alpha
quotient)
NTB: memory, attention,
choice reaction time.

qEEG (resting, eyes
closed)
NTB: MMSE, FAB

MRI regional grey matter
volume [15]
MRI whole brain atrophy
[19, 20]
NTB: CDR-SOB, MMSE,
HVLT-R (delayed recall),
category fluency
(animals).

Neuroimaging and
neuropsychological
measures

Table 3: Continued.

Open, case
series study.

Randomised,
doubleblind,
placebocontrolled
trial.

Cognition: significant improvement in
cognitive function following 1 month and 2
months and maintained following 3
months of GBE.
Significant improvement in choice reaction
time following 1 month and maintained
following 2 and 3 months of GBE.
Neuroimaging: significant reduction in
theta wave component of theta/alpha
quotient following 1 month and maintained
following 2 and 3 months of GBE.

Randomised,
doubleblind,
placebocontrolled
trial
(VITACOG
study).

Study design

Cognition: significant improvement in
cognitive function (FAB).
Neuroimaging: relative alpha power
increased in temporal regions for
responders versus nonresponders.
Suggests increased frontal lobe function.

Efficacy on cognition, neuroimaging
measures, any associations, adherence,
retention, and adverse events
Neuroimaging: significantly reduced brain
atrophy (0.5% versus 3.7%) in posterior
brain regions (bilateral hippocampus,
parahippocampal gyrus, retrosplenial
precuneus, lingual and fusiform gyrus,
cerebellum). Rate of brain atrophy was
significantly slower (by 29.6%) with
B-vitamin treatment than placebo.
This effect was even greater (53% lower
atrophy) for individuals with high baseline
tHcy, a risk factor for brain atrophy.
This effect was also even greater (40%
lower atrophy) for individuals with high
baseline 𝜔-3 fatty acid concentrations, a
risk factor for brain atrophy.
Adherence: >78% took at least 75% of the
tablets; 81.4% (70/84 active, 66/83 placebo)
determined biologically compliant via
blood samples.
Retention: total 20 withdrew (11x B-vit, 9x
placebo). Total 15 lost to death or cancer
(7x B-vit, 8x placebo). Further 8 lost or
excluded for “miscellaneous” reasons (5x
B-vit, 3x placebo).
Adverse effects: no significant safety issues
or group differences in adverse events.
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Aim: to investigate
Muresanu et persistence of the effects
al. (2010) [24], of cerebrolysin on
Romania
cognition & qEEG in
people with VaD.

VaD (𝑁 = 33):
randomised (2 : 3 : 3) to
cerebrolysin 10 mL
(4M : 9F, 72.46 ± 2.80 yrs,
MMSE 18.92 ± 1.32),
cerebrolysin 30 mL
(7M : 4F, 70.36 ± 3.62 yrs,
MMSE 20.27 ± 1.92), or
placebo (5M : 4F, 71.89 ±
3.52 yrs, MMSE 18.89 ±
1.81).

Cognition: no change in executive
function, memory, sensorimotor speed, or
attention.
Neuroimaging: increased or reduced
atrophy in GM volume for target versus
control intervention (middle and superior
frontal cortices, frontal pole, angular
cortex, posterior cingulate cortex).
Significant decrease in total homocysteine
concentration.
Retention/adherence: original 𝑁 = 35;
𝑛 = 13 discontinued due to time
constraints or poor compliance.
Adverse effects: None.

Efficacy on cognition, neuroimaging
measures, any associations, adherence,
retention, and adverse events

Cognition: significant improvement in
cognitive performance maintained at
follow-up.
Neuroimaging: significant
(dose-dependent) reduction in qEEG
power ratio maintained at follow-up.
Retention/adherence: original study
𝑁 = 41; 𝑛 = 8 lost to follow-up or due to
poor compliance (i.e., receiving new drug
treatment).

Cognition: no change in MMSE scores
(trend toward improved orientation to
place).
Neuroimaging: significant increase in
rCBF (SPECT)
rCBF in posterior cingulate.
NTB: MMSE, NPI, PSMS. Retention/adherence: original 𝑁 = 13;
𝑛 = 5 discontinued due to poor
compliance, change in location, or
withdrawal.
Adverse effects: none.

MRI brain volume
NTB: digit span, TMT,
Stroop, AVLT, verbal
fluency.

Neuroimaging and
neuropsychological
measures

Intervention: 50 mL i.v.
infusions of cerebrolysin
(10 mL + 40 mL saline or
qEEG, eyes closed resting
30 mL + 20 mL saline) or
state
placebo (saline) 5 days/wk. NTB: MMSE, ADAS-cog.
Duration: 4 weeks.
Follow-up: 12 weeks (±1).

Aim: to investigate the
effect of
Matsuoka et toki-shakuyaku-san
MCI/AD (𝑛 = 8; 3M : 5F, Intervention: 7.5 g TSS,
al. (2012) [23], (TSS) on rCBF in people 77.8 ± 4.9 yrs, MMSE 23.4 orally (powder).
Japan
with MCI or AD.
± 3.6).
Duration: daily for 8 wks.
Recruitment location:
university clinic.

Köbe et al.
(2015) [22],
Germany

Intervention and duration

Intervention: both target
and control groups
received omega-3 FA
(2.2 g/d; 4x oral capsules
daily).
Target intervention:
aerobic training (cycle
Aim: to investigate the
ergometer; 2 × 45 min/wk)
combined effects of
MCI (𝑁 = 22):
+ cognitive stimulation
omega-3 fatty acids (FA), randomised to target
(AKTIVA: Aktive Kognitive
aerobic exercise, and
intervention (9M : 4F, 70.0 Stimulation-Vorbeugung im
cognitive stimulation on ± 7.2 yrs, MMSE 28.5 ± 1.1) Alter (active cognitive
brain atrophy in people or control intervention
stimulation-prevention in
with MCI.
(5M : 4F, 70.0 ± 5.2 yrs,
the elderly); 1x individual +
Recruitment location:
MMSE 27.9 ± 1.7).
12x group sessions, 90 min
memory clinics.
duration, plus daily home
practice, beginning week
4).
Control intervention:
nonaerobic training
(stretching & toning; 2 ×
45 min/wk).
Duration: 6 months.

Study population

Aim, recruitment

Author
(reference)

Table 3: Continued.

Open-label
extension of
a
randomised,
doubleblind,
placebocontrolled
trial.

Open, case
series study.

Randomised
controlled
trial

Study design
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Study population

Mild to severe dementia
(𝑁 = 29 (VaD: 𝑛 = 13;
AD: 𝑛 = 7, mixed 𝑛 = 9);
15M : 14F, 78.9 ± 6.8 yrs;
MMSE 9–23).

AD (𝑁 = 10; 65 ± 8 yrs;
MMSE 16.0 ± 5.1).

Aim, recruitment

Aim: to investigate the
effect of cobalamin
(vitamin B12) treatment
on brain function in
people with a medical
history of cognitive
deterioration.
Recruitment location:
hospital outpatients.

Aim: to investigate the
effect of traditional
Chinese medicine
treatment on brain
function in people with
AD.

Mild to severe AD
(𝑁 = 60 completed): first
divided into mild AD
(group I) versus
moderate-severe AD
(group II) then
randomised to treatment:
group I DPZ (6M : 9F, 65.2
Aim: to test the effects of ± 1.8 yrs, MMSE 21.5 ±
donepezil (DPZ) versus 0.4, ADAS-Cog 22.3 ±
vitamin E on brain
1.0), Group I vit E
function in people with (7M : 8F, 65.5 ± 1.7 yrs,
varying severities of AD. MMSE 21.5 ± 0.6,
ADAS-Cog 22.5 ± 0.9),
Group II DPZ (6M : 9F,
66.7 ± 1.5 yrs, MMSE 11.5
± 0.6, ADAS-Cog 44.5 ±
1.2), Group II vit E
(8M : 7F, 66.5 ± 1.6 yrs,
MMSE 11.6 ± 0.4,
ADAS-Cog 43.5 ± 1.4).

Author
(reference)

Nilsson et al.
(2000) [25],
Sweden

Oishi et al.
(1998) [26],
Japan

Onofrj et al.
(2002) [27],
Italy

ERP (P300 auditory
oddball)
NTB: MMSE, ADAS-cog,
WAIS.

ERP (auditory oddball
P300)
rCBF (stable xenon CT
method)
NTB: MMSE.

Intervention: traditional
Chinese medicine
(astragalus root 8 g,
Prunella vulgaris 3 g,
pueraria root 9 g, Lycii
fructus 8 g, cnidium
rhizome 5 g, rhubarb 1 g,
alisma rhizome 6 g, peach
kernel 6 g, ginseng 3 g,
oyster shell 8 g).
Duration: 3 months.

Titration: 14 days, 5 mg/day
DPZ or 1000 IU/day vit E,
orally.
Intervention: 10 mg/day
DPZ or 2000 IU/day vit E,
orally.
Duration: 6 months.

rCBF (xenon 133
inhalation and
cortexplorer with 254
scintillation detectors)
NTB: MMSE, OBS.

Neuroimaging and
neuropsychological
measures

Intervention:
intramuscular injection of
hydroxycobalamin (vit.
B12); 1 mg every second
day, total 10x.
Duration: 1 month.

Intervention and duration

Table 3: Continued.

Cognition: DPZ: significant improvement
in neuropsychological test performance,
regardless of AD severity, though more
pronounced for moderate-severe than mild
AD.
Vitamin E: severe deterioration of
neuropsychological test performance,
regardless of AD severity.
Neuroimaging: DPZ: significantly reduced
P300 latency, regardless of AD severity,
though more pronounced for
moderate-severe than mild AD.
Vitamin E: significantly increased P300
latency, regardless of AD severity.
Retention/adherence: total 7 withdrew
during initial titration phase (6x DPZ
(adverse effects), 1x Vit E
(noncompliance)).
Adverse effects: 6x DPZ (3x nausea or
abdominal discomfort, 3x confused
agitation).

Cognition: significant improvement in
MMSE scores (though still below normal
range).
Neuroimaging: significantly improved
(shortened) P300 latency. Increased white
matter CBF.
Adverse effects: none.

Pseudorandomised,
doubleblind,
controlled
trial.

Open, case
series study.

Efficacy on cognition, neuroimaging
measures, any associations, adherence,
Study design
retention, and adverse events
Cognition: 𝑁 = 15 classified as “clinically
improved” (orientation to time and space,
recent memory), though dementia severity
did not change. 𝑁 = 14 did not show any
Open, case
clinical improvements.
series study.
Neuroimaging: 𝑁 = 15 “clinically
improved” had significant increase in
general blood flow level. 𝑁 = 14 slight
trend towards a decrease in blood flow.
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Aim: to test the efficacy
of nicergoline (NIC) in
people with unspecified
dementia (all-cause).
Recruitment location:
nursing home for
seniors.

Saletu et al.
(1995) [20],
Austria

Titration: 1 month, 5 mg/d
DPZ, 2000 IU/d vit E, or
1.5 mg/d Riv, orally.
Intervention: 10 mg/d DPZ
or 2000 IU/d vit E, orally.
Riv: 1x capsule 2x/d; month
2: total 3 mg/d, month 3:
total 6 mg/d, month 4: total
9 mg/d, months 5 & 6: total
12 mg/d.
Duration: 6 months.
Follow-up: each month.

Intervention: 2 × 30 mg
NIC (or placebo) per day,
orally.
Duration: 8 weeks NIC or
placebo, 2-week washout
period.

Mild to moderate
dementia (𝑁 = 112,
MMSE 13–25; equal
distribution SDAT : MID
(𝑛 = 56), equally
randomised (𝑛 = 28) to
placebo control (PLAC)
or treatment (NIC)):
SDAT/NIC: 5M : 23F, 78 ±
7 yrs; SDAT/PLAC:
7M : 21F, 77 ± 10 yrs;
MID/NIC: 6M : 22F, 81 ±
7 yrs; MID/PLAC:
9M : 19F, 79 ± 7 yrs.

Mild to moderately severe
AD (𝑁 = 60): randomised
to double-blind treatment
(DPZ (9M : 11F, 66.50 ±
9.19 yrs, MMSE 16.0 ± 0.5,
ADAS-Cog 33.34 ± 2.70)
or vit E (10M : 10F, 65.50 ±
Aim: to test the effects of
10.61 yrs, MMSE 16.0 ±
donepezil (DPZ) versus
Thomas et al.
0.5, ADAS-Cog 33.45 ±
vitamin E versus
(2001) [28],
2.60)), or open trial Riv
rivastigmine (Riv) on
Italy
(9M : 11F, 65.00 ± 8.49 yrs,
brain function in people
MMSE 16.0 ± 0.5,
with AD.
ADAS-Cog 33.39 ± 2.70).
Age-matched control
group (𝑁 = 60):
25M : 35F, 67.50 ±
14.85 yrs, MMSE 29.0 ±
0.4, ADAS-Cog 14.25 ±
0.50.

Intervention and duration

Study population

Aim, recruitment

Author
(reference)

Cognition: DPZ and Riv: significant
improvement in neuropsychological test
performance.
Vitamin E: severe deterioration of
neuropsychological test performance.
Neuroimaging: DPZ and Riv: significant
reduction in P300 latency (no difference
ERP (P300 auditory
between).
oddball)
Vitamin E: significantly increased P300
NTB: MMSE, ADAS-Cog, latency.
WAIS subscales.
P300 latency changes were significantly
correlated with neuropsychological test
scores.
Retention/adherence: total 4 withdrew
from Riv (3x nausea, 1x noncompliance).
Total 2 excluded from vit E (no detectable
P300).
Adverse effects: 3x nausea.

Efficacy on cognition, neuroimaging
measures, any associations, adherence,
retention, and adverse events
Cognition: significant improvements in
CGI, MMSE, and SCAG (versus
pretreatment and placebo group).
Neuroimaging: decreased relative power
delta/theta and alpha-1, increased relative
power alpha-2 and beta (right temporal to
frontotemporal and left parietal and
temporo-occipital regions) (versus
opposite effects in placebo).
Suggests improved vigilance.
Acceleration of total centroid power
EEG mapping (3 min
spectrum (versus pre- and placebo).
V-EEG)
Shortened latency of P300 (versus pre- and
ERP (P300 auditory
placebo).
oddball)
Suggests improved information processing.
NTB: MMSE, SCAG, CGI. Retention: total 14 withdrew: 4x
SDAT/NIC, 4x SDAT/PLAC, 4x MID/NIC,
2x MID/PLAC.
Responder to nonresponder ratio:
SDAT/NIC 16 : 8 (i.e., 66.6% responders),
SDAT/PLAC 8 : 16, MID/NIC 17 : 7 (i.e.,
70.83% responders), MID/PLAC 7 : 19.
Adverse effects: 9 of 48 NIC reported
adverse effects (mild or marked insomnia
(×2), mild itching, blocked nose, sweating,
dry mouth, diarrhea, weight loss,
constipation, moderate rigor).

Neuroimaging and
neuropsychological
measures

Table 3: Continued.

Randomised
three-arm
trial with one
open-label
arm and two
double-blind
arms.

Randomised,
doubleblind,
placebocontrolled
crossover
trial.

Study design
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Aim, recruitment
aMCI (𝑁 = 35): Crocus
(5M : 12F, 71.47 ± 6.73 yrs,
MMSE 27.41 ± 1.70, MoCA
22.91 ± 3.00) or wait-list
control (4M : 14F, 69.72 ±
7.33 yrs, MMSE 27.89 ±
1.84, MoCA 22.81 ± 2.64).

Study population

Intervention: Crocus (no
further information
available).
Follow-up: 12 months.

Intervention and duration

Intervention: 3x choto-san
extract (TJ-47, Tsumura,
7.5 g/day) orally, daily
[contains 4.5 g of extract of
11 kinds of dried medical
herbs: Uncariae Uncis
Cum Ramulus (3 g hooks
and branch of Uncaria
sinensis Oliver), Aurantii
Nobilis pericarpium (3 g
peel of Citrus unshiu
Markovich), Pinelliae
tuber (3 g tuber of Pinellia
ternate Breitenbach),
Ophiopgonis tuber (3 g
Aim: to test the effects of
root of Ophiopogon
VaD/MCI (𝑁 = 20):
choto-san on brain
japonicus Ker-Gawler),
Yamaguchi et
choto-san (8M : 2F, 71.3 ±
function in people with
Hoelen (3 g fungus of Poria
al. (2004) [30],
9.8 yrs, MMSE 23.8 ± 3.6)
VaD/MCI.
cocos Wolf), Ginseng radix
Japan
or control (9M : 1F, 68.0 ±
Recruitment location:
(2 g root of Panax ginseng
8.6 yrs, MMSE 26.8 ± 2.8).
hospital outpatients.
C.A. Meyer),
Chrysanthemi flow (2 g
flower of Chrysanthemum
morifolium Ramatulle),
Saphoshnikoviae radix (2 g
root and rhizome of
Saposhnikovia divaricata
Schischkin), Glycyrrhizae
radix (1 g root of
Glycyrrhiza uralensis
Fisher), Gypsum Fibrosum
(5 g CaSO4 2H2 O) and
Zingiberis rhizoma (1 g,
rhizome of Zingiber
officinale Roscoe)].
Duration: 12 weeks.

Aim: to test the effects of
Crocus sativus L.
(saffron) on brain
Tsolaki et al.
function in people with
(in press) [29],
aMCI.
Greece
Recruitment location:
outpatient memory &
dementia clinic.

Author
(reference)

ERP (P300 novelty
auditory oddball)
NTB: MMSE, verbal
fluency test.

Neuroimaging and
neuropsychological
measures
MRI (global maxima of
case “a”; 𝑛 = 8 subgroup)
ERP (P300 novelty
auditory oddball using
HD-EEG (256 channel);
𝑛 = 6 subgroup)
NTB: MMSE, MoCA,
NPI, activities of daily
living.

Table 3: Continued.

Cognition: significantly faster RT and
increased accuracy on auditory oddball
task. Significant improvement in MMSE
and verbal fluency.
Neuroimaging: Significant reduction in
P300 latency.
Trend towards increased novelty P300
amplitude.

Cognition: significant improvement in
MMSE (versus nonsignificant decline in
the wait-list group).
Neuroimaging: significantly greater left
temporal inferior gyrus volume.
Significantly reduced P300 latency.

Efficacy on cognition, neuroimaging
measures, any associations, adherence,
retention, and adverse events

Open,
cohort study.

Single-blind,
nonrandomised,
waitlistcontrolled
pilot trial.

Study design
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Intervention: 4 × 300 mg
BSC [main components
Zexie (Alismatis rhizoma)
and Roucongrong
(Cistanches Herba)] or 4x
placebo tablet, 3x/day.
Duration: 3 months.

Intervention: 4x CCRC
[main components
Cistanche and Polygonum
multiflorum thunb] or 4x
placebo tablet, 3x/day or
nothing (control).
Duration: 3 months.

aMCI (𝑁 = 44):
randomised to BSC
(12M : 10F, 65.05 ±
6.67 yrs, MMSE 26.27 ±
1.58) or placebo (11M : 11F,
62.41 ± 5.76 yrs, MMSE
26.45 ± 1.40).

aMCI (𝑁 = 41):
randomised to CCRC
(8M : 8F, 64.25 ± 7.10 yrs,
MMSE 26.38 ± 1.50),
placebo (4M : 6F, 60.20 ±
3.52 yrs, MMSE 26.70 ±
1.64), or control (6M : 7F,
60.08 ± 6.53 yrs, MMSE
26.77 ± 1.30).

VaD (𝑁 = 80: 46M : 34F,
66.5 ± 5.6 yrs) randomised
to GBT (𝑛 = 40) or aspirin
(𝑛 = 40).

Aim: to investigate the
effect of Bushen capsule
(BSC) on brain function
in people with aMCI.
Recruitment location:
hospital and community.

Aim: to investigate the
effect of Congrongyizhi
capsule (CCRC) on
brain function in people
with aMCI.
Recruitment location:
hospital and community.

Aim: to investigate the
effect of Ginkgo biloba
(EGb761) on brain
activity in people with
VaD.
Recruitment location:
hospital.

Zhang et al.
(2015) [31],
China

Zhang et al.
(2014) [32],
China

Zhang et al.
(2012) [33],
China

rCBF (transcranial
Doppler)
NBT: Montreal cognitive
assessment (MoCA).

fMRI (n-back task).
NTB: MMSE, AVLT,
CVLT, stroop, digit span,
clock drawing.

fMRI (episodic memory
encoding task).
NTB: MMSE, AVLT,
CVLT, Stroop, digit
symbol, clock drawing.

Neuroimaging and
neuropsychological
measures
Efficacy on cognition, neuroimaging
measures, any associations, adherence,
retention, and adverse events
Cognition: significant improvement in
MMSE, stroop, and AVLT.
Neuroimaging: increased brain activation
in right putamen; this was significantly
associated with stroop performance.
Reduced brain deactivation in right middle
temporal gyrus; this was significantly
associated with AVLT performance.
Adverse effects: 1x decreased appetite for 3
days (BSC), 1x mild nausea for 1 week
(placebo). Neither discontinued use or
withdrew from study.
Cognition: significant improvement in
MMSE and digit span, which were
significantly associated with increased
brain deactivation in posterior cingulate
cortex.
Neuroimaging: increased brain
deactivation in posterior cingulate cortex,
inferior frontal gyrus, and lingual gyrus.
Adverse effects: 1x decreased appetite for 3
days (CCRC), 1x mild nausea for 1 week
(placebo). Neither discontinued use or
withdrew from study.
Cognition: significant improvement in
global score MoCA, as well as MoCA score
indices for executive function, attention,
delayed memory, and orientation.
Neuroimaging: significant increase in
blood flow velocity in middle and anterior
cerebral arteries.

Randomised,
controlled
trial.

Randomised,
doubleblind,
placebocontrolled
trial.

Randomised,
doubleblind,
placebocontrolled
trial

Study design

Note. ACC = anterior cingulate cortex; AD = Alzheimer’s disease; ADAS-Cog = Alzheimer’s Disease Assessment Scale–cognitive subscale; aMCI = amnestic mild cognitive impairment; AVLT = Auditory Verbal
Learning Test; BNT = Boston Naming Test; CGI = clinical global impression; COWAT = Controlled Oral Word Association Test; CVLT = California Verbal Learning Test; d = day (i.e., /d = per day); DMN =
default mode networks; DRS = Dementia Rating Scale; EEG = electroencephalography; ERP = event-related potential; FAB = frontal assessment battery; F : M = females to males; fMRI = functional magnetic
resonance imaging; GM = grey matter; HVLT-R = Hopkins Verbal Learning Test-Revised; MCI = mild cognitive impairment; MFG = medial frontal gyrus; MID = multi-infarct dementia; MMSE = Mini-Mental
State Examination; MoCA = Montreal cognitive assessment; MRI = magnetic resonance imaging; MTG = medial tegmental gyrus; NPI = Neuropsychiatric Inventory; NTB = neuropsychological test battery; OBS
= Organic Brain Syndrome Scale; PCC = posterior cingulate cortex; PET = positron emission tomography; PSMS = Physical Self-Maintenance Scale; RAVLT = Rey Auditory Verbal Learning Test; rCBF = regional
cerebral blood flow; RCFT = Rey Complex Figure Test; rCMRglc = regional cerebral metabolic rate of glucose consumption; ReHo = regional homogeneity; RT = reaction time; SCAG = Sandoz Clinical AssessmentGeriatric; SDAT = senile dementia of the Alzheimer type; SH = subcortical/periventricular hypertensity; SPECT = single-photon emission computed tomography; tHcy = total homocysteine; TMT = Trail Making
Test; VaD = vascular dementia; V-EEG = vigilance-controlled EEG; yrs = years (i.e., age in years); WAIS-R = Wechsler Adult Intelligence Scale–Revised; WMS-R = Wechsler Memory Scale–Revised.

Intervention: 19.2 mg GBT
+ 75 mg aspirin or 75 mg
aspirin tablet, 3x/day.
Duration: 3 months.

Intervention and duration

Study population

Aim, recruitment

Author
(reference)

Table 3: Continued.
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Table 4: Risk of bias ratings for included studies. Studies are detailed in alphabetical order of authors’ names. Studies with low risk of bias
(total scores ≥ 9) are italicised.
Study
Bi et al. (2011)
Cohen et al. (2003)
de Waal et al. (2014)
Douaud et al. (2013)
Heo et al. (2016)
Hofferberth (1994)
Jernerén et al. (2015)
Köbe et al. (2015)
Matsuoka et al. (2012)
Muresanu et al. (2010)
Nilsson et al. (2000)
Oishi et al. (1998)
Onofrj et al. (2002)
Saletu et al. (1995)
Smith et al. (2010)
Thomas et al. (2001)
Tsolaki et al. (in press)
Yamaguchi et al. (2004)
Zhang et al. (2015)
Zhang et al. (2014)
Zhang et al. (2012)

Item 1
0
0
1
1
0
0
1
0
0
0
0
0
0
0
1
1
0
0
0
0
1

Item 2
0
0
1
1
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
0

Item 3
1
1
1
1
1
0
1
1
1
1
1
0
1
1
1
0
0
0
1
1
1

Item 4
0
0
1
1
0
0
1
0
0
0
0
0
1
0
1
0
0
0
1
1
0

Item 5
1
1
1
1
0
0
1
0
1
0
1
0
1
1
1
1
0
0
0
0
1

Item 6
1
1
1
1
0
0
1
1
1
0
1
0
0
0
1
1
0
0
1
1
0

Item 7
1
1
1
1
0
0
1
1
1
1
0
0
0
1
1
1
0
0
1
1
0

Item 8
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1

Item 9
0
0
1
1
1
0
1
1
1
0
0
1
1
1
1
0
0
0
1
1
0

Item 10
0
0
1
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0

Total
5
5
10
9
3
1
9
5
6
3
4
2
5
6
10
5
1
1
6
6
4

Note. Items rated as yes scored 1, and items rated as no or unable to determine both scored 0. Lower scores indicate a higher risk of bias.

of which 13 were in the form of a tablet/capsule [14, 16–
22, 27, 28, 31–33], 3 as a granular or powder extract [13, 23, 30],
1 as a drink [15], and 2 with no details of the preparation
method (traditional Chinese medicine [26] and Crocus [29]).
One of those studies was a multidomain intervention with
omega-3 fatty acid supplementation, aerobic training, and
cognitive stimulation [22]. One study gave intramuscular
injections [25] and 1 intravenous infusions [24].
3.2.4. Neuroimaging Techniques. Ten studies used EEG [15,
19–21, 24, 26–30], 5 used MRI [14, 16–18, 22], 2 used fMRI [31,
32], 1 used SPECT [23] and another PET [13], and 3 studies
measured CBF [25, 26, 33]. One CBF study employed xenon
133 inhalation and high resolution scintillation detectors
(Cortexplorer) [25], 1 used transcranial Doppler (TCD) [33],
and the other used stable xenon CT; that study also recorded
EEG [26]. One other study combined methods: EEG and MRI
[29].
A range of analyses were conducted for EEG, MRI, and
fMRI studies. For the EEG studies, 1 examined functional
connectivity using phase lag index [15], 2 studies assessed
relative power with quantitative EEG (qEEG) from an eyes
closed resting state condition [21, 24], 1 study examined
theta/alpha ratio [19], and 6 studies assessed P300 ERP component amplitudes and latencies from an auditory oddball
task [20, 26–30], 1 of which also analysed N200 [29], and
another also employed a 3-minute vigilance task and assessed
absolute and relative power [20]. For the MRI studies, 1 examined whole brain volume and subcortical and periventricular

hyperintensities [14], 1 regional volumetric changes [29],
2 examined regional grey matter volume [16, 22], and 2
examined whole brain atrophy [17, 18]. Of the 2 fMRI studies,
both assessed blood oxygenation level dependent (BOLD)
responses, 1 with an episodic memory encoding task [31], and
another with an n-back task [32].
3.2.5. Measures of Cognition. A variety of neuropsychological
measures were used to assess cognition. The most common
were the MMSE (𝑛 = 20) [13–18, 20–33], Alzheimer’s Dementia Assessment Scale-cognitive subscale (ADAS-cog; 𝑛 = 4)
[13, 24, 27, 28], Hopkins Verbal Learning Test (HVLT-R; 𝑛 =
4) [16–18], Auditory Verbal Learning Test (𝑛 = 3) [22, 31, 32],
Rey Auditory Verbal Learning Test (𝑛 = 1) [15], California
Verbal Learning Test (𝑛 = 3) [14, 31, 32], Stroop Test (𝑛 = 3)
[22, 31, 32], Trail Making Test (𝑛 = 3) [14, 15, 22], Clinical
Dementia Rating-Sum of Boxes (CDR-SOB; 𝑛 = 3) [16–18],
and Category Fluency (𝑛 = 3) [16–18]. Please refer to Table 3
for other neuropsychological tests used.
3.2.6. Compliance, Withdrawals, and Adverse Events. Nine
studies reported on compliance [15–18, 22–24, 27, 28], 14
reported on withdrawals (loss to follow-up) [13–18, 20, 22–
24, 27, 28, 31, 32], and 11 reported on adverse events [13, 16–
18, 20, 22, 23, 26, 27, 31, 32]. Information on the reporting of
compliance, withdrawals, and adverse events is summarised
in Table 3.
3.3. Risk of Bias within and across Studies. Table 4 details the
results for the risk of bias assessment (refer to Table 2 for
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items assessed). Although 13 studies were randomised [13–
18, 20, 24, 27, 28, 31–33], only 5 studies detailed how the
randomisation procedure was conducted [15–18, 28], and 4 of
those studies reported specific information on the allocation
concealment [15–18]. Participant characteristics including
how the diagnosis of cognitive decline, MCI, or dementia was
made or confirmed, and inclusion and exclusion criteria were
described in 16 studies [13–18, 20–25, 27, 31–33]. Seven studies
reported on blinding of participants, intervention deliverers,
and researchers collecting data [15–18, 27, 31, 32]. Only 12
out of the 21 studies provided sufficient information on the
intervention to allow replication [13–18, 20, 23, 25, 27, 28,
33], and only 12 described neuroimaging methodologies and
analyses sufficiently to allow replication [13–18, 22, 23, 25, 28,
31, 32]. Thirteen studies used appropriate, valid, and reliable
outcome measures [13–18, 20, 22–24, 28, 31, 32]. The majority
of studies did not selectively report [13–33]. Adverse events
were reported in 12 studies [15–18, 20–23, 26, 27, 31, 32], and
only 3 studies reported a power calculation, all of which were
sufficiently powered to detect an effect [15, 18, 20].
3.3.1. Intervention Efficacy in Low Risk of Bias Studies. Four
of the 21 studies were reported particularly well and demonstrated a low risk of bias (scoring ≥ 9) [15–18]. Three of
those studies were reporting on findings from the same randomised, double-blind, placebo-controlled trial (VITACOG)
[16–18] investigating the effects of 2 years of high dose
vitamin B treatment for people with MCI, and the other
was a randomised, double-blind, placebo-controlled 24-week
international multisite clinical trial [15] on Souvenaid for
AD. All 4 studies incorporated a relatively comprehensive
neuropsychological test battery, rather than just a simple
global measure of cognition (e.g., ADAS-cog, MMSE). One of
those studies reported on EEG network connectivity [15], and
the other 3 reported structural MRI: regional grey matter volume [16] and whole brain atrophy [17, 18]. One study found
a reduction in EEG beta network integrity in the placebo,
but not the intervention group, indicating counteraction of
network decline after 24 weeks of 125 mL/day Souvenaid in
people with AD [15]. The other 3 studies showed a reduction
in regional grey matter and whole brain atrophy after 2 years
treatment with high dose vitamin B (0.8 mg/day folic acid,
20 mg/day vitamin B6, 0.5 mg/day vitamin B12) for people
with MCI, compared to placebo [16–18].
Three of the 4 studies reported associations between
cognitive test scores and neuroimaging outcome measures
[15, 16, 18]. In 1 study, an association between EEG beta
activity and memory performance (𝑧-score across NTB; see
Table 3) was reported at midpoint in the Souvenaid group
only [15]. An association between rate of atrophy and both
final MMSE scores and baseline Telephone Interview of
Cognitive Status-Modified (TICS-M) scores was reported in
one of the high dose vitamin B studies [18]. There was also
an association between increased grey matter loss and lower
MMSE and CDR-SOB scores and poorer delayed recall and
category fluency performance [16] in another of the vitamin
B studies.
3.4. Efficacy on Neuroimaging Measures across All Studies.
Eighteen studies reported positive neuroimaging findings
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associated with CM treatment [13, 15–26, 29–33] (8 MCI
studies, 6 AD studies, 3 VaD studies, and 1 all-cause dementia
study) and three reported negative findings [14, 27, 28] (2
AD studies and 1 VaD study). The key patterns of results are
outlined below; for more detailed information on results not
reported in the review body, please refer to Table 3.
Out of the 6 studies that assessed auditory oddball P300
ERP component amplitudes and latencies, 4 reported reduced
P300 latencies [20, 26, 29, 30] and 2 reported increased P300
amplitudes [29, 30] after CM treatment (12 weeks of traditional Chinese medicine versus no comparison group [26];
8 weeks of 60 mg/day nicergoline cf. placebo [20]; 12 weeks of
7.5 g/day Choto-san extract [TJ-47] versus no treatment [30];
52 weeks of Crocus extract versus waitlist [29]). Two other
studies [27, 28] reported similar changes in the control condition: both reported increased P300 amplitudes (26 weeks of
5 mg/day donepezil [27, 28] or 1.5 mg/day rivastigmine [28]),
and 1 reported reduced P300 latencies (26 weeks of 5 mg/day
donepezil) [27]. Those two studies also showed a decrease in
P300 amplitude and an increase in latency following 26 weeks
of 2000 IU/day vitamin E [27, 28]. Theta was significantly
reduced in the theta/alpha quotient after 12-weeks treatment
with 80 mg/day standardised ginkgo biloba extract (EGb761)
in one study [19], and another study reported decreased beta
network EEG in the placebo but not the intervention group
(24 weeks of 125 mL/day Souvenaid) [15].
One MRI study showed significantly increased whole
brain volume after 26 weeks of the target multimodal intervention (see Table 3 for details) and reduced volume for the
control group [22], and another study showed no difference
in whole brain volume between treatment (52 weeks of 1 g/day
citicoline) and placebo [14]. One fMRI study reported both
increased BOLD response in the right putamen and reduced
BOLD in the right middle temporal gyrus when participants
completed an episodic memory encoding task after 1.2 g/day
Bushen for 12 weeks [31].
One CBF study reported an increase in white matter CBF
with stable xenon CT after 12 weeks of a traditional Chinese
medicine [26], and one TCD CBF study reported increased
blood flow velocity to the middle and anterior cerebral
arteries after 12 weeks of 19.2 mg/day EGb 761 standardised
ginkgo extract and 75 mg/day aspirin [33].
3.5. Efficacy on Cognition across All Studies. Across all studies, 13 reported positive effects on cognition [13, 19–21, 23–
26, 29–33], 4 studies reported negative results [14, 22, 27, 28],
and 4 did not report on cognition findings alone [15–18]. As
detailed above in Section 3.4, the key patterns of results for the
commonly used neuropsychological tests are detailed below,
with further information available in Table 3. Two studies
[13, 24] reported improvements (a reduction) in ADAS-cog
scores in the intervention group (12 weeks of 10 g/day
fuzhisan [13]; 4 weeks of 10 mL/day Cerebrolysin [24]), and 1
in the control group (26 weeks of 10 mg/day donepezil [27]),
and another showed a significant deterioration in ADAScog scores following treatment in the CM arm (26 weeks
of 2000 IU/day Vitamin E) but noted improvements in the
other two parallel arms (5 mg/day donepezil and 1.5 mg/day
rivastigmine) [28].
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Five studies [20, 26, 30–32] reported significantly
improved MMSE scores after treatment (12 weeks of a traditional Chinese medicine [26]; 8 weeks of 60 mg/day nicergoline [20]; 12 weeks of 22.5 g/day TJ-47 Choto-san extract [30];
12 weeks of 1.2 g/day bushen [31]; 12 weeks of 3/day Congrongyizhi capsules [32]) and another showed a trend towards
improved MMSE scores following 8 weeks of 7.5 g/day of
toki-shakuyaku-san powder [23]. One study reported no changes in cognition following 6 months of a multimodal intervention [22].
3.6. Associations between Neuroimaging and Cognitive Measures. Six of 21 studies reported associations between measures of cognition and neuroimaging markers [15–18, 31,
32]. One study showed a relationship between activation
in the right putamen during an episodic memory task and
Stroop performance, and reduced middle temporal gyrus
deactivation with AVLT performance [31]. Another study
showed that greater posterior cingulate cortex deactivation
was associated with improved MMSE and digit span scores
[32].
Four studies did not report neuropsychological test
battery findings alone as they had already been published
previously [15–18]. For example, one of those studies reported
an association between memory performance and EEG beta
band activity at the midpoint of the 24-week Souvenaid trial
(125 mL/day) [15]. Please see Table 3 for more detailed information on studies reporting associations between clinical and
neuroimaging findings.

4. Discussion
This systematic review summarised and critically appraised
intervention studies that incorporated neuroimaging outcome measures to assess nutritional and herbal medicines
for MCI and dementia. The majority of studies focused on
participants with AD [13, 15, 19, 21, 23, 25–28] or MCI [16, 17,
22, 23, 29, 31, 32], utilised a herbal medicine [13, 19, 21, 23, 26,
29–33], a 12-week long intervention [13, 19, 21, 26, 30–33], and
incorporated EEG [15, 19–21, 24, 26–30] or structural MRI
[14, 16–18, 22] as a neuroimaging technique. All but 3 studies
[14, 27, 28] reported positive neuroimaging results following
CM treatment [13, 15–26, 29–33], despite most (𝑛 = 17)
studies having a high risk of bias, scoring ≤ 6 out of 10 on the
risk of bias assessment [13, 14, 19–33]. Given the importance of
using neuroimaging markers in the assessment of endpoints
for clinical trials in dementia [35], particularly with a move
towards preclinical disease phases [36], and the viable role
that CMs can play as potential treatments, it is imperative
that the rigour and quality of CM dementia studies using
neuroimaging techniques is improved. This discussion will
now focus separately on the three aims of this review: (1)
study characteristics; (2) methodologies; and (3) intervention
efficacy. To address risk of bias, an additional discussion on
study quality has also been included. In light of the findings
from this systematic review, a series of key recommendations
for improving future work in this area is detailed in Box 1.
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4.1. Study Characteristics
4.1.1. Participants. The majority of studies reported information on how a diagnosis of MCI or dementia was made or
confirmed and included sufficient inclusion and exclusion
criteria to allow replication [13–18, 20–25, 27, 31–33]; one
study did not detail cognitive status of the control group
[30]. Important demographic information, such as years of
education, a factor known to significantly increase the risk
of dementia [37], was missing from other studies [19, 28]. In
order to meaningfully assess the efficacy of an intervention,
it is essential that the tested cohort is as homogeneous as
possible. This can be done by closely following guidelines
stipulating the most up-to-date diagnostic criteria for MCI
[38], dementia (relative to the type; e.g., McKhann et al. [39]),
and subjective cognitive complaints [40], and by carefully
recording and reporting all relevant participant demographics and baseline characteristics. Care must also be taken to
match participant characteristics between active and control
groups, with one study not detailing information on the
cognitive status of the control group, making comparison
impossible [30].
4.1.2. Study Setting. The majority of studies recruited from
memory clinics [14, 15, 22, 29], hospitals [13, 23, 33], the
community [16–18], or a combination of those settings [31,
32]. However, 5 studies did not report the recruitment setting
[19, 24, 26–28]. The recruitment setting for dementia studies
has been shown to dramatically influence the participant
characteristics and health outcomes. For example, participants with MCI recruited from a memory clinic have been
shown to have an annual conversion rate to dementia that is
10% higher than participants recruited from the community
[41]. Thus, future work in this field should ensure that the
recruitment setting is carefully considered in study design
and reported adequately in the published results.
4.1.3. Intervention. The majority of studies tested a Chinese
herbal medicine [13, 19, 21, 23, 26, 30–33] or a vitamin [16–18,
25, 27, 28] intervention, with most using a tablet or capsule for
oral administration [14, 16–22, 27, 28, 31–33]. Only just over
half the studies reported enough detail for the intervention
to be replicated [13–18, 20, 23, 25, 27, 28, 33]. The main
difficulty here was that, for herbal medicines, standardisation
did not occur [26, 30], or the details were not supplied. For
the latter, this included missing information on the particular
standardised formula used (e.g., EGb 761 for Ginkgo biloba),
missing information on dose or dosing regimen, and/or
inadequate information on commercially available extracts
(e.g., brand/manufacturer) [19, 21, 22, 26, 29–32]. Quality
control and quality assurance (Good Manufacturing Practice
[GMP]) is required for psychopharmacological research,
and the absence of complete information on intervention
formulation makes results near impossible to replicate. This
problem is further compounded when multi-herb formulas
are used, as a greater degree of preclinical work is required to
develop standard operating procedures (SOPs) for extraction
methods, and to optimise ratios of individual constituents.
It should also be noted that treatment duration varied
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(1) Study Characteristics:
(a) Research needs to follow the most recent guidelines stipulating diagnostic criteria for subjective cognitive complaints, MCI,
and dementia, and should be closely adhered to when formulating protocols to ensure that the study population is as homogeneous
as possible.
(b) Essential baseline characteristics, particularly ones known to increase the risk of dementia, should be reported.
(c) Recruitment setting needs to be carefully considered and always reported.
(2) Methodologies:
(a) All information on neuroimaging data collection, pre- and post-processing pipelines, and quantification needs to be reported
to ensure that the results can be adequately scrutinised and replicated.
(b) Optimal analytic techniques should be utilised for the quantification of neuroimaging data.
(c) Standardised neuropsychological tests that are appropriate clinical trial endpoints for the level of cognitive impairment
should be used.
(3) Intervention Efficacy:
(a) Standardised herbal extracts should be used to reduce the variability between studies.
(b) Multi-herb formulas require substantial preclinical research to optimise ratios of active components, and determine their
efficacy and safety as a formula.
(c) Dosage should be kept similar to other research (unless there is a rationale for adjusting dose) to reduce variability between
studies.
(d) The length of trials should be carefully determined and have a rationale to allow for greater comparability between studies.
(e) An appropriate control group, such as a placebo matched to colour, shape, taste and smell of the active treatment, should
always be included.
Box 1: Recommendations for future chronic CM neuroimaging research on people with MCI or dementia.

substantially between studies from 4 weeks [24, 25] to 2 years
[16–18], adding further complexity to comparisons between
studies.
4.1.4. Study Design. Although the majority of studies included a control group [13–20, 22, 24, 27–33], four studies did
not [21, 23, 25, 26], rendering a high risk of bias. A control
group, such as a placebo, should always be incorporated to
establish whether a true relationship between the treatment
and outcome actually exists. In the context of herbal medicine
research, appropriate placebos are often difficult to establish
because they need to match the active treatment on taste,
smell, look, and feel. Herbal medicines can be pungent and
have a distinctive taste so additional care needs to be taken
when matching to a placebo [42].
4.2. Methodology
4.2.1. Structural and Functional Neuroimaging Methods. Most
studies incorporated functional neuroimaging methods [13,
15, 19–21, 23–28, 30–33], largely EEG [15, 19–21, 24, 26–
30]. There were large differences in the tasks and analytic
methods described in these studies, but the majority of
EEG papers assessed auditory oddball P300 ERP component
amplitudes and latencies [20, 26–30]. The P300 has been
widely explored in ERP literature and has been associated
with a range of cognitive processes including memory [43],
the orienting of attention [44], decision-making [45], and
expectancy [46, 47]. The studies assessing P300 in this review
largely reported baseline-to-peak quantification methods
(when quantification was described at all), despite this
being an ineffective approach for disentangling the multiple
subcomponents comprised within the monolithic P300 peak

(i.e., P3a, P3b, Novelty P3, and Slow Wave) that represent
a range of cognitive processes [48]. Given that effect sizes
from CMs can be small [49], and that interventions may
affect various cognitive domains, it is imperative that optimal
analytic methods are employed to maximise the chance of
detecting an effect. Alternative component quantification
methods, such as Principal Components Analysis (PCA),
should be adopted for future CM ERP studies [50].
Neuroimaging data acquisition, pre- and postprocessing
pipelines, and analyses were adequately reported in only
12 of 21 studies [13–18, 22, 23, 25, 28, 31, 32]. There was
insufficient information on how the data were collected (e.g.,
recording parameters, task details including length of resting
state condition, and stimulus delivery) [19–21, 24, 26, 30, 33],
inadequate reporting of pre- and postprocessing techniques
that are in line with widely accepted best practice (e.g.,
artefact rejection) [21, 29], and missing data quantification
details (e.g., Fast Fourier Transformation [FFT] parameters,
quantification of P300) [24, 26]. Given the potential limitations of some neuroimaging techniques (as outlined in
Table 1), it is imperative that future work describes all data
acquisition, processing, and analytic techniques to ensure
that variability in results between studies can be adequately
accounted for.
Although the majority of studies reported positive results
[13, 15–26, 29–33], as noted above, the quality of reporting
in most of these studies was relatively poor, indicating a
high risk of bias. The results and conclusions from those
studies should be viewed with a degree of caution. Given that
functional neuroimaging methods are often more sensitive
than standard pen-and-paper tests, it is even more important
that high quality data, analyses, and interpretations are
reported.
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4.2.2. Measures of Cognition. The majority of studies utilised
the MMSE [13–18, 20–28, 30–33], ADAS-cog [13, 24, 27, 28],
and tested verbal learning [14–18, 22, 31, 32]. Similar to the
neuroimaging results, most studies reported positive effects
on cognition [13, 19–21, 23–26, 30–33], even though the
risk of bias assessment indicated that only 13 studies used
appropriate outcome measures [13–18, 20, 22–24, 28, 31, 32].
For example, it has been argued that the MMSE is not
appropriate for cognitive assessments in people with MCI
due to its low sensitivity (18%) in that cohort [51]. However,
all but 1 [17] of the 7 MCI studies included here reported
MMSE scores. These shortcomings make it challenging to
meaningfully interpret the efficacy on cognition of the CMs
reviewed here. The 4 studies that scored a low risk of bias
utilised comprehensive neuropsychological test batteries [15–
18] and did not report on the efficacy of these cognitive outcome measures as they had already been reported previously
when the complete results of those RCTs were published
elsewhere. Future work should also utilise a comprehensive
neuropsychological test battery and use outcome measures
that are appropriate clinical trial endpoints for the level of
cognitive impairment of the target cohort [52].
4.3. Study Quality and Risk of Bias. The majority of studies
assessed in this systematic review were at high risk of bias
[13, 14, 19–33]. One of the most common (and significant)
issues was that a power calculation was not reported in the
majority of studies (Table 4). Most studies had a relatively
small sample size and were consequently at risk of Type
II error (false negative). The 3 studies that did conduct a
power calculation all achieved their recruitment target [15,
18, 20]. Bias also came from a lack of reporting on how
randomisation and allocation concealment were carried out.
Most studies were randomised trials [13–18, 20, 24, 27, 28, 31–
33]; however, only a small number of these actually reported
on the randomisation procedure [15–18, 28] and an even
smaller number on how allocation was concealed [15–18].
Randomisation allows for the distribution of participant
characteristics to be left to chance. Without adequate randomisation, it cannot be assumed that the null hypothesis
(that participant groups have been drawn from the same
population) is true [53]; this jeopardises internal validity. In
relation to allocation concealment, given that most studies
utilised an oral intervention, there is no reason that similar
future work should not report how allocation was concealed
and who was blinded. It must be acknowledged that this is
not always the case in some physical activity interventions
[22], where allocation concealment can be challenging. A
further source of bias came from the lack of reporting of
adverse events, which was done by only 12 studies [15–18, 20–
23, 26, 27, 31, 32]. Future work should always report adverse
events that may have been due to the intervention as it ensures
the safety of participants.
4.4. Intervention Efficacy. The focus of the 4 high quality
studies that scored a low risk of bias [15–18] was to report
detailed analyses of neuroimaging secondary outcome measures. Of those four studies, 3 reported that 2-year treatment
for MCI with high dose vitamin B (0.8 mg/day folic acid,

Evidence-Based Complementary and Alternative Medicine
20 mg/day vitamin B6, and 0.5 mg/day vitamin B12) reduced
whole brain and regional grey matter atrophy, compared to
placebo [16–18], and 1 found that 24 weeks of 125 mL/day
Souvenaid maintained EEG beta network integrity in people
with AD, where this declined in the placebo group [15].
Three of those studies also reported an association
between cognitive test scores and neuroimaging outcome
measures [15, 16, 18]. It was found that lower MMSE, CDRSOB, delayed recall, and category fluency scores were associated with accelerated grey matter loss in one of the high dose
vitamin B studies [16]. Baseline TICS-M and final MMSE
scores were associated with rate of atrophy in another high
dose vitamin B study [18], and midpoint memory performance was associated with beta activity in the Souvenaid
study [15]. In terms of clinical use, the above studies indicate
that 2 years of high dose vitamin B or 6 months of 125 mL/day
Souvenaid have potential clinical utility as an adjunct therapy
for people with MCI or Alzheimer’s disease, respectively.
4.5. Recommendations. This systematic review has identified
a number of consistent shortcomings in CM neuroimaging
research into cognitive decline. In an effort to improve the
rigour and validity of this important and developing field, the
authors suggest 11 key recommendations emerging from the
3 review aims that future work should adhere to. These are
detailed in Box 1.
4.6. Strengths and Limitations. This systematic review focused on studies reporting a chronic intervention only. Acute
studies may necessarily utilise a different range of neuroimaging methods than those reported here. For example, structural MRI is not appropriate for acute treatment
administration as structural brain changes take longer than
a few hours to be detected. Future research should systematically summarise and critically appraise acute CM studies
[54, 55] to provide a more comprehensive overview of the
field. Furthermore, the heterogeneity of the interventions
and neuroimaging techniques employed made meta-analyses
impossible here. Future work (with a different aim) could
consider focusing on only one intervention or neuroimaging
modality in order to quantify efficacy. It should also be noted
that the authors of included studies were not contacted by the
authors of this review.
This review not only focused on efficacy but also on summarising the characteristics of studies, intervention efficacy,
and methods utilised. Particular consideration was given to
identifying risks of bias. Neuroimaging and CM are a rapidly
evolving area of research; thus the findings reported here
highlight a number of significant strengths and weaknesses
in this field that can be addressed in future work in an effort
to improve the evidence base.
4.7. Conclusions. This systematic review summarised and
critically appraised CM research on people with cognitive
decline, MCI, or dementia that incorporated neuroimaging as
an outcome measure. It was found that most studies focused
on people with AD, utilised a herbal medicine intervention
that was on average 12 weeks long, and used EEG or structural
MRI as neuroimaging outcome measures. Nearly all studies
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reported positive results, despite the majority having a high
risk of bias. The most common issues were a lack of reporting
on randomisation, allocation concealment, blinding, and the
lack of a power calculation. Eleven recommendations to improve future neuroimaging CM research on people with MCI
and dementia have been highlighted in the recommendations
box. The authors hope that the pragmatic approach taken
to this systematic review will lead to an uptake of these
recommendations and a subsequent increase in the quality of
CM neuroimaging research on people with MCI or dementia.
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